CTLA4 and neoplasm: Interestingly, the tumor immunoediting induced by anti-PD-1 or anti-PD-1/anti-CTLA-4 therapies has also been related to a loss of dominant mutation-associated neoantigens in initially responding patients that developed acquired resistance, suggesting the further evolution to tumors with diminished immunogenicity [74].